Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind, randomized, controlled contraceptives, parallel group, to assess the effect on nerve fibers in patients diagnosed with endometriosis grade III / IV symptomatic ascending-dose oral quinagolide for 16 weeks Estudio doble ciego, aleatorizado, controlado con anticonceptivos, de grupos paralelos, para evaluar el efecto sobre las fibras nerviosas en pacientes diagnosticadas de endometriosis grado III/IV sintomática con quinagolida oral a dosis ascendentes durante 16 semanas

Trial Profile

Double-blind, randomized, controlled contraceptives, parallel group, to assess the effect on nerve fibers in patients diagnosed with endometriosis grade III / IV symptomatic ascending-dose oral quinagolide for 16 weeks Estudio doble ciego, aleatorizado, controlado con anticonceptivos, de grupos paralelos, para evaluar el efecto sobre las fibras nerviosas en pacientes diagnosticadas de endometriosis grado III/IV sintomática con quinagolida oral a dosis ascendentes durante 16 semanas

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Jan 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quinagolide (Primary) ; Drospirenone
  • Indications Endometriosis
  • Focus Pharmacodynamics; Therapeutic Use

Most Recent Events

  • 07 Jan 2013 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top